Multiple Myeloma Market Size (7MM) was estimated to be nearly USD 21,300 million in 2023, which is expected to show positive growth by 2034, estimated DelveInsight

DelveInsight's "Multiple Myeloma Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of multiple myeloma, historical and forecasted epidemiology as well as Multiple Myeloma therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Discover more about the multiple myeloma market in detail @ Multiple Myeloma Market Report- https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Multiple Myeloma Market Report
• In September 2025, Lupin received U.S. FDA approval for its generic Lenalidomide Capsules (2.5-25 mg), a treatment for multiple myeloma and certain cases of myelodysplastic syndromes (MDS). The product, bioequivalent to Bristol-Myers Squibb's Revlimid®, will be manufactured at Lupin's Pithampur facility in India.
• In August 2025, Regeneron Pharmaceuticals highlighted its PD-1 inhibitor Libtayo as the standard of care for advanced cutaneous squamous cell carcinoma (CSCC), with ongoing research in melanoma and multiple myeloma.
• In May 2025, GSK announced that the CHMP of the EMA recommended approval of Blenrep for adults with relapsed or refractory multiple myeloma. The recommendation covers use with bortezomib and dexamethasone (BVd) for patients with at least one prior therapy, and with pomalidomide and dexamethasone (BPd) for those previously treated with lenalidomide. A final decision from the European Commission is expected in Q3 2025.
• In May 2025, Johnson & Johnson announced that the FDA's Oncologic Drugs Advisory Committee (ODAC) voted 6-2 in favor of the benefit-risk profile of DARZALEX FASPRO® for treating high-risk smoldering multiple myeloma (HR-SMM). The FDA application for this indication was submitted in November 2024.
• The total Multiple Myeloma Incidence in the 7MM comprised nearly 75,000 in 2023 and are projected to increase during the forecast period.
• In the 7MM, the highest multiple myeloma incidence was seen in the United States, followed by EU4 and the UK.
• Among EU4 and the UK, Germany accounted for the highest number of incident cases of multiple myeloma, whereas Spain accounted for the lowest in 2023.
• Multiple myeloma is more common in males as compared to females. More than 50% of males in the United States are diagnosed with multiple myeloma.
• Data suggests that roughly half of newly diagnosed multiple myeloma patients are ineligible for transplant, and around a third of eligible patients do not receive the transplant. In the US, there were around 23,600 frontline transplant-ineligible patients and 9,200 transplant-eligible patients of multiple myeloma patients in 2023.
• Regarding age-specific cases of Multiple myeloma, the age group of 65 and above has the highest number of cases accounting for more than 70% of cases in the United States, followed by 55-64 and 0-54 years.
• The leading Multiple Myeloma Companies such as Sanofi, Karyopharm Therapeutics, AbbVie, Takeda Pharmaceutical, Celgene, Bristol-Myers Squibb, RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Celgene, Aduro Biotech, ExCellThera, Janssen Pharmaceutical, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners AG, Chipscreen Biosciences, AbbVie/Genentech (Roche), Janssen Biotech, Nanjing Legend Biotech, Merck Sharp & Dohme Corp., Janssen, Regeneron Pharmaceuticals, Bristol-Myers Squibb, Cartesian Therapeutics, AstraZeneca, Abbvie (Pharmacyclics) and Johnson & Johnson, MorphoSys AG/I-Mab Biopharma and others.
• Promising Multiple Myeloma Therapies such as CARVYKTI (ciltacabtagene autoleucel), TALVEY (talquetamab), Mezigdomide (CC-92480), Linvoseltamab (REGN5458) and others.

For a comprehensive view of the CAR T-cell therapy for multiple myeloma market, check out the CAR T-Cell Therapy for Multiple Myeloma Market Assessment- https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Epidemiology Segmentation in the 7MM
• Total Multiple Myeloma Incident Cases
• Total Multiple Myeloma Symptomatic Cases
• Multiple Myeloma Gender-Specific Cases
• Multiple Myeloma Age-Specific Cases
• Multiple Myeloma Transplant-Eligible Cases
• Multiple Myeloma Treated patient pool across all lines of therapies

Discover more about refractory multiple myeloma drugs in development @ Refractory Multiple Myeloma Clinical Trials- https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Multiple Myeloma Marketed Drugs
• CARVYKTI (ciltacabtagene autoleucel): Johnson & Johnson Innovative Medicine
CARVYKTI is a B-cell maturation antigen (BCMA)-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient's T cells with a transgene encoding a chimeric antigen receptor (CAR) that identifies and eliminates cells that express BCMA. In April 2024, Johnson & Johnson announced that the US FDA approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with RRMM who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. In February 2022, Johnson & Johnson Innovative Medicine announced that the US FDA had approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

• TALVEY (talquetamab): Johnson & Johnson Innovative Medicine
TALVEY is a bispecific T-cell engaging antibody that binds to the CD3 receptor expressed on the surface of T cells and G protein-coupled receptor class C group 5 member D (GPRC5D), a novel multiple myeloma target which is highly expressed on the surface of multiple myeloma cells and non-malignant plasma cells, as well as some healthy tissues such as epithelial cells of the skin and tongue. TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Emerging Multiple Myeloma Drugs
• Mezigdomide (CC-92480): Bristol Myers Squibb
Mezigdomide is a highly potent modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities. Mezigdomide binds to cereblon (CRBN) upon administration, affecting the ubiquitin E3 ligase activity and targeting certain substrate proteins for ubiquitination. This induces proteasome-mediated degradation of certain transcription factors, some of which are transcriptional repressors in T cells. The company is evaluating the drug in different clinical trials in different lines of therapies for treating NDMM and RRMM. In January 2023, the company initiated the Phase III trial of CC-92480 in combination with carfilzomib and dexamethasone (480kd) vs. carfilzomib and dexamethasone in 2L+ participants with RRMM (SUCCESSOR-2). The company is expecting the first approval of mezigdomide by 2026-2027.

• Linvoseltamab (REGN5458): Regeneron
Linvoseltamab is a BCMAxCD3 bispecific antibody in patients with RRMM. It is designed to bind to BCMA on multiple myeloma cells and the CD3 receptor on T cells, bridging them together and activating T-cell killing of the cancer cell. The drug is designed to closely resemble natural human antibodies, using Regeneron's proprietary 'human antibody mouse' technology (VelocImmune) and 'full-length bispecific antibody' platform (VelociBi). The linvoseltamab clinical development program includes a Phase III confirmatory trial in patients with R/R MM (LINKER-MM3) that is currently enrolling. Additional trials in earlier lines of therapy and stages of disease are planned or underway, including a Phase I/II trial in the first-line setting, a Phase II trial in high-risk smoldering MM, and a Phase II trial in monoclonal gammopathy of undetermined significance. Apart from that, a Phase I trial of linvoseltamab in combination with a Regeneron CD38xCD28 costimulatory bispecific in MM is also planned. In February 2024, the company announced that the US FDA had accepted for priority review the Biologics License Application (BLA) for linvoseltamab to treat adult patients with RRMM that has progressed after at least three prior therapies. Moreover, the target action date for the FDA decision is August 22, 2024.

To gain a deeper understanding of the RRMM market, be sure to explore the Relapsing Refractory Multiple Myeloma Market Outlook- https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Multiple Myeloma Market Dynamics
The Multiple Myeloma market dynamics are shaped by the increasing prevalence of multiple myeloma, increasing demand for effective treatments, the high cost of novel therapies, and the ongoing need for clinical trials to validate new treatment regimens. As research continues, the focus remains on improving patient outcomes and quality of life through personalized treatment strategies.

Multiple Myeloma Treatment Market
The existing multiple myeloma treatment is mainly dominated by classes such as Proteasome Inhibitors, Immunomodulating Agents, Monoclonal Antibodies, Nuclear export inhibitors, CAR-T cell therapy, and Bi-specific antibodies. Apart from these classes, Histone Deacetylase (HDAC) inhibitors were also included in the treatment regimen, but now it has been withdrawn from the US market.

To know more about Multiple Myeloma companies working in the treatment market, visit @ Multiple Myeloma Clinical Trials and Therapeutic Assessment- https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Multiple Myeloma Market Outlook
At present, the market holds a diverse range of therapeutic alternatives for treatment, which includes Proteasome Inhibitors, Immunomodulating Agents, Histone Deacetylase (HDAC) inhibitors, Monoclonal Antibodies, Chemotherapy, Corticosteroids, Nuclear export inhibitors, CAR-T cell therapy, and Bispecific antibody in different lines of treatment. For several decades, the standard therapy for multiple myeloma included a combination of alkylating agents, primarily melphalan and cyclophosphamide, together with corticosteroids, such as dexamethasone and prednisone, all of which were augmented in the mid-1980s by the introduction of autologous stem cell transplantation.

Multiple Myeloma Companies
Sanofi, Karyopharm Therapeutics, AbbVie, Takeda Pharmaceutical, Celgene, Bristol-Myers Squibb, RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Celgene, Aduro Biotech, ExCellThera, Janssen Pharmaceutical, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners AG, Chipscreen Biosciences, AbbVie/Genentech (Roche), Janssen Biotech, Nanjing Legend Biotech, Merck Sharp & Dohme Corp., Janssen, Regeneron Pharmaceuticals, Bristol-Myers Squibb, Cartesian Therapeutics, AstraZeneca, Abbvie (Pharmacyclics) and Johnson & Johnson, MorphoSys AG/I-Mab Biopharma and others.

Discover more about therapies set to grab major Multiple Myeloma Market Share @ Multiple Myeloma Treatment Market- https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Multiple Myeloma Market Report
• Coverage- 7MM
• Study Period - 2020-2034
• Multiple Myeloma Companies- Sanofi, Karyopharm Therapeutics, AbbVie, Takeda Pharmaceutical, Celgene, Bristol-Myers Squibb, RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Celgene, Aduro Biotech, ExCellThera, Janssen Pharmaceutical, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners AG, Chipscreen Biosciences, AbbVie/Genentech (Roche), Janssen Biotech, Nanjing Legend Biotech, Merck Sharp & Dohme Corp., Janssen, Regeneron Pharmaceuticals, Bristol-Myers Squibb, Cartesian Therapeutics, AstraZeneca, Abbvie (Pharmacyclics) and Johnson & Johnson, MorphoSys AG/I-Mab Biopharma and others.
• Multiple Myeloma Therapies- CARVYKTI (ciltacabtagene autoleucel), TALVEY (talquetamab), Mezigdomide (CC-92480), Linvoseltamab (REGN5458) and others.
• Multiple Myeloma Therapeutic Assessment: Multiple Myeloma current marketed and Multiple Myeloma emerging therapies
• Multiple Myeloma Market Dynamics: Multiple Myeloma market drivers and Multiple Myeloma market barriers
• Multiple Myeloma Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Multiple Myeloma Unmet Needs, KOL's views, Analyst's views, Multiple Myeloma Market Access and Reimbursement

Discover more about therapies set to grab major Multiple Myeloma Market Share @ Multiple Myeloma Treatment Market- https://www.delveinsight.com/sample-request/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. KEY INSIGHTS
2. REPORT INTRODUCTION
3. EXECUTIVE SUMMARY
4. MULTIPLE MYELOMA MARKET OVERVIEW AT A GLANCE
5. KEY EVENTS
6. EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY
7. MULTIPLE MYELOMA BACKGROUND AND OVERVIEW
8. EPIDEMIOLOGY AND PATIENT POPULATION
9. PATIENT JOURNEY
10. KEY ENDPOINTS IN MULTIPLE MYELOMA
11. MULTIPLE MYELOMA MARKETED DRUGS
12. MULTIPLE MYELOMA EMERGING THERAPIES
13. MULTIPLE MYELOMA: 7MM MARKET ANALYSIS
14. MULTIPLE MYELOMA UNMET NEEDS
15. SWOT ANALYSIS
16. KOL VIEWS
17. MARKET ACCESS AND REIMBURSEMENT
18. APPENDIX
19. DELVEINSIGHT CAPABILITIES
20. DISCLAIMER
21. ABOUT DELVEINSIGHT

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.